文献速递脊柱关节炎

银屑病关节炎的新靶向治疗进展

New targets in psoriatic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2016-01-01

本文综述银屑病关节炎(PsA)的新靶向治疗进展,涵盖IL-17抑制剂司库奇尤单抗、抗IL-23药物乌司奴单抗,以及合成药物磷酸二酯酶-4抑制剂阿普司特和Janus激酶抑制剂托法替布。部分新药对皮肤的疗效可能优于关节。

要点

  • IL-17抑制剂和抗IL-23药物是PsA生物制剂新靶点。
  • 阿普司特和托法替布为PsA合成DMARD新选择。
  • 部分新药对皮肤疗效可能优于关节。

核心结论

  • PsA新靶向治疗包括IL-17抑制剂、抗IL-23药物、PDE4抑制剂和JAK抑制剂。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 司库奇尤单抗(IL-17抑制剂)和乌司奴单抗(抗IL-23)为PsA生物制剂新进展。
  • 阿普司特(PDE4抑制剂)和托法替布(主要抑制Jak3和Jak1,较少抑制Jak2)为合成药物新进展。
  • 部分新药对皮肤疗效可能优于关节。

临床怎么用

  • 传统治疗包括NSAIDs、局部和全身糖皮质激素、合成及生物DMARDs。
  • 达标治疗策略已成功用于PsA。
  • 近十年生物制剂以TNF-α抑制剂为主(英夫利西单抗、依那西普、阿达木单抗、 certolizumab和戈利木单抗)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PsA is an immune-mediated chronic inflammatory disease that affects both skin and joints; it is a heterogeneous disease characterized by synovitis, enthesitis, dactylitis and spondylitis. The impact on patients and the burden of disease are substantial. For assessment of the disease, patient-reported outcomes are increasingly important. Conventional therapy consists of NSAIDs, local and systemic CSs, and synthetic and biological DMARDs. While MTX, LEF, SSZ and CYC are the synthetic drugs mainly used, TNF-α blocking agents have represented the majority of biologics used in the last decade (infliximab, etanercept, adalimumab, certolizumab and golimumab). Treat-to-target strategies have been used successfully in PsA. This review concentrates on new developments, mainly covering biologic agents with an IL-17 inhibitor (secukinumab) and an anti-IL-23 agent (ustekinumab), but also synthetic drugs, including a novel phosphodiesterase-4 inhibitor (apremilast) and a Janus kinase inhibitor (tofacitinib) that blocks mainly Jak3 and Jak1 and, to a lesser extent, Jak2. The efficacy of some of these new agents may be even better for the skin than for the joints.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Braun J. New targets in psoriatic arthritis. Rheumatology (Oxford). 2016. PMID: 27856658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。